Loading organizations...
§ Private Profile · Watertown, MA, USA
Biotechnology company developing immunotherapies and mRNA vaccines for lifelong protection from cancer and infectious diseases.
Corner Therapeutics is a Watertown, Massachusetts-based biotechnology company that develops novel immunotherapies, including mRNA-based vaccines and dendritic cell stimuli platforms, to treat cancer and infectious diseases. The firm utilizes proprietary technologies designed to hyperactivate dendritic cells, inducing durable T cell and antibody responses that build upon foundational innate immunity research. Operating within the oncology and infectious disease markets, the enterprise partners with various biopharmaceutical firms and nonprofit organizations to advance its clinical development pipeline. The company has raised $54 million in Series A equity funding, supported by lead investor Ziff Capital Partners and the Bill and Melinda Gates Foundation. Its strategic development is guided by a scientific advisory board featuring prominent industry figures such as John Maraganore and Arlene Sharpe. Corner Therapeutics was founded in 2020 by Andrew Bellinger, Jonathan Kagan, and Steven Altschuler.
Corner Therapeutics has raised $54.0M across 1 funding round.
Corner Therapeutics has raised $54.0M in total across 1 funding round.
Corner Therapeutics has raised $54.0M across 1 funding round. Most recently, it raised $54.0M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 19, 2024 | $54M Series A | Ziff Capital Partners | Sandia Holdings, Tanis Venture Management | Announced |
Corner Therapeutics has raised $54.0M in total across 1 funding round.
Corner Therapeutics's investors include Ziff Capital Partners, Sandia Holdings, Tanis Venture Management.